Company

Intarcia Therapeutics

Signal active

Organization

Contact Information

Overview

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides.

Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity.

David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

About

Industries

Biotechnology, Health Care, Medical Device, Personal Health, Health Diagnostics

Founded

1997

Employees

251-500

Headquarters locations

United States, North America

Social

N/A

Profile Resume

Intarcia Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical Device, Personal Health, Health Diagnostics sector. The company focuses on Biotechnology and has secured $774.4B in funding across 460 round(s). With a team of 251-500 employees, Intarcia Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Intarcia Therapeutics, raised $50.0M. Discover more about their projects, partnerships, and impact on our platform.

Employees

Dick Ford

Executive Director, DUROS® Manufacturing

Robert Lemmon

Executive Director, Regulatory Compliance and Quality Assurance

Gino Santini

Board Member

Jay Smith

CXO- Chief Experience Officer- Head of Customer experience and Outcomes

Andrew Young

Vice President & Chief Scientific Officer

Ved Srivastava

Vice President, Chemistry

Funding Rounds

Funding rounds

Investors

Lead Investors

Total Funding Amount

$1683.5M

Details

Intarcia Therapeutics has raised a total of $1683.5M in funding over 8 rounds.

Announcement date	Transaction name	Money raised
2016	Late Stage Venture	206.0M
2016	Late Stage Venture	215.0M
2003	Late Stage Venture	43.0M
2004	Late Stage Venture	50.0M

Investors

Intarcia Therapeutics is funded by 65 investors.

Investor Name	Lead Investor	Funding Round	Partners
Notable Capital	-	FUNDING ROUND - Notable Capital	50.0M
Bryan Roberts	-	FUNDING ROUND - Bryan Roberts	50.0M
Intarcia Therapeutics	-	FUNDING ROUND - Intarcia Therapeutics	50.0M
Venrock	-	FUNDING ROUND - Venrock	50.0M

Recent Activity

There is no recent news or activity for this profile.